Coronary Angioplasty & Stenting

For most single-vessel or two-vessel coronary artery disease, angioplasty with drug-eluting stenting is preferred over bypass surgery — it is less invasive, has a shorter recovery, and achieves equivalent outcomes for most patients. For complex three-vessel disease or left main disease, the SYNTAX and EXCEL trials show bypass surgery may offer better long-term results in selected patients with high SYNTAX scores. The decision is individualised — Dr. Amit Singh will recommend the option the evidence supports for your specific anatomy.

IVUS (Intravascular Ultrasound) places a miniature ultrasound probe inside the coronary artery to visualise the vessel wall in cross-section during the procedure. This allows the cardiologist to correctly size the stent, confirm complete expansion, and detect complications invisible on plain angiography. The RENOVATE trial (NEJM 2023, 1,639 patients) demonstrated IVUS-guided PCI led to 36% fewer target-vessel failures (cardiac death, target-vessel MI, repeat revascularisation) versus angiography-guided PCI alone. Dr. Amit Singh uses IVUS or OCT guidance routinely at Kokilaben Hospital, Koperkhairne.

A coronary stent is a permanent metallic implant — it stays in the artery for life and does not need replacement. Modern drug-eluting stents have a restenosis (re-narrowing) rate of less than 5% at one year, compared to 20–40% for older bare-metal stents. With proper dual antiplatelet therapy and cardiovascular risk factor control (statins, blood pressure management, diabetes control, smoking cessation), most patients do not require repeat intervention in the stented segment.

DAPT means taking two antiplatelet medications simultaneously — aspirin plus clopidogrel, ticagrelor, or prasugrel. After drug-eluting stent placement, ACC/AHA guidelines recommend 6–12 months of DAPT for stable coronary artery disease and 12 months after a heart attack. DAPT prevents blood clots from forming on the stent while it heals. Never stop DAPT early without consulting your cardiologist — premature cessation is the leading cause of acute stent thrombosis, a serious complication.

After radial-approach coronary angioplasty, most patients are mobile within 1–2 hours and discharged the same day or after an overnight stay. Avoid heavy lifting and strenuous exercise for 1–2 weeks. Return to desk work is typically possible within 3–5 days. Driving is permitted after 24–48 hours. Full physical activity is resumed within 2–4 weeks. Follow-up is at 1 month, 3 months, and annually.

Yes — coronary angioplasty is safe and effective in diabetic patients. Diabetic patients often have more calcified and diffuse coronary disease, requiring advanced techniques such as IVUS/OCT guidance, intravascular lithotripsy (IVL), or rotational atherectomy. Modern everolimus-eluting stents perform well in diabetic vasculature. Metformin should be stopped 24–48 hours before and restarted 48 hours after the procedure, once kidney function is confirmed stable.

Yes. Coronary angioplasty and stenting is a listed procedure covered by most Indian health insurance policies, including cashless treatment. CGHS, ECHS, and Ayushman Bharat PM-JAY cover the procedure for eligible patients at Kokilaben Dhirubhai Ambani Hospital, Koperkhairne. Most private health insurers (Star Health, New India, ICICI Lombard, HDFC Ergo) also provide coverage. Pre-authorisation from your insurer is typically required before the procedure. Contact Heartwise Cardiology on 9769517636 for insurance guidance.

Coronary angioplasty is a safe, routinely performed procedure with a major complication rate of less than 1% at experienced centres. Stroke risk is less than 0.1%. Emergency surgery is required in less than 0.1% of cases. The procedure is performed in a dedicated Cardiac Catheterisation Laboratory at Kokilaben Hospital, Koperkhairne, with continuous monitoring, full resuscitation equipment, and an experienced interventional cardiology team. The radial (wrist) access approach causes far fewer access-site complications than femoral access (RIVAL trial: large haematomas HR 0.40, pseudoaneurysms needing closure HR 0.30).

The SYNTAX score quantifies the anatomical complexity of coronary artery disease by weighting the number, location, and morphological characteristics of each coronary lesion. A score of 22 or below (low complexity) generally favours coronary angioplasty and stenting. A score of 23–32 (intermediate complexity) is individualised based on additional clinical factors. A score of 33 or above (high complexity) typically indicates that coronary artery bypass grafting (CABG) is likely to produce superior long-term outcomes. The SYNTAX score works alongside fractional flow reserve (FFR): FFR determines whether an individual lesion is significant enough to treat, while the SYNTAX score determines the overall revascularisation strategy.

No — they are distinct complications with different timing and mechanisms. Stent thrombosis is a sudden, acute blood clot forming inside the stent, often presenting as a new heart attack; it is the complication that dual antiplatelet therapy (DAPT) is specifically designed to prevent. In-stent restenosis is a gradual process, occurring over months to years, where scar tissue slowly re-narrows the vessel inside the stent — typically presenting as recurrent angina rather than a sudden event. Stent thrombosis is a clotting failure; restenosis is a healing-response failure.